These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
    Author: Tan G, Wang ZY, Yin S.
    Journal: Zhonghua Yi Xue Za Zhi; 2006 Apr 11; 86(14):943-6. PubMed ID: 16759530.
    Abstract:
    OBJECTIVE: To investigate the therapeutic effects on pancreatic carcinoma by dendritic cells (DCs) transfected with interleukin (IL)-23 and acquiring apoptotic cell antigen. METHODS: Murine IL-23 cDNA was subcloned into the vector so as to construct the eukaryotic dual-gene repression vector pcDNA3-IL-23. Bone-derived DCs were obtained from the long bones of extremities of normal C(57)BL/6 mice and were transfected with pcDNA3-IL-23. DCs cultured routinely and IL-23-transfected DCs were co-cultured with apoptotic tumor cells for 24 h so as to collect sensitized DCs acquiring the antigen of the apoptotic cells. Primary pancreatic carcinoma models were created in C(57)BL/6 mice with dimethyl-benzanthracene so as to obtain suspension of tumor cells. Thirty C(57)BL/6 mice were randomly divided into 5 groups: Group I (IL-23-transfected DC vaccine group, to be injected subcutaneously with IL-23 and apoptotic cells-modified DC vaccine twice with an interval of 7 d), Group II (apoptotic cells-sensitized DC vaccine group, to be injected subcutaneously with apoptotic cells-modified DC vaccine), Group III (IL-23 transfected DC group, to be injected with IL-23 transfected DCs), Group IV (un-modified DC group, to be injected with un-modified DCs), and Group V (control group, injected with normal saline). Seven days after the second injection suspension of tumor cells was injected subcutaneously, and then tumorigenesis was observed every other day. Another 30 C(57)BL/6 mice were divided into 5 groups as above-mentioned (Groups I - V(1)) and were killed 1 week after the inoculation of tumor cell suspension. Their spleens were taken out. The cytotoxic lymphocytes (CTLs) were isolated, co-cultured with IL-25 and apoptotic cells, and then tested for the secretion of interferon (IFN)-gamma and IL-4 by ELISA. Thirty C(57)BL/6 mice loading pancreatic carcinoma were randomly divided into 5 groups as above-mentioned (Groups I - V(2)) so as to observe the survival time. RESULTS: ELISA showed that the IFN-gamma expression in the supernatant of culture fluid of IL-23 transfected DCs in Groups I(1) was significantly up-regulated (P < 0.01), and the IL-4 secretion of Group I(1) and Groups III(1) were both significantly lower than that of Group II(1) (both P < 0.05). The CTL civilities of Group I(1) and II(1) were both significantly higher than those of the other 3 groups (all P < 0.05). Four weeks after the inoculation tumorigenesis was not seen in Group I and was seen in Groups III and IV with an incidence of 33% - 50%. Tumorigenesis occurred only 1 week later in Group V. The tumor sizes of Groups I(2) and II(2) were both significantly smaller than those of the other 3 groups and the survival times of Groups I(2) and II(2) were both significantly lower than those of the other 3 groups (all P < 0.01). CONCLUSION: IL-23 helps enhance the presenting ability of DC antigen. IL-23 modified vaccine strengthens the immune response of CTLs against specific tumor, thus inducing defensive immune response in the host and strengthening their active immune ability.
    [Abstract] [Full Text] [Related] [New Search]